乙型肝炎核心抗体定量水平的临床研究进展  

CLINICAL RESEARCH ADVANCES IN THE QUANTIFICATION OF HEPATITIS B CORE ANTIBODY

作　　者：王亚平[1] 杜忠彩 张凤娟[1] 刘培[1] 牛庆慧[1] 边城[1] WANG Yaping;DU Zhongcai;ZHANG Fengjuan;LIU Pei;NIU Qinghui;BIAN Cheng(Department of Infectious Diseases,The Affiliated Hospital of Qingdao University,Qingdao 266003,China)

机构地区：[1]青岛大学附属医院感染性疾病科,山东青岛266003

出　　处：《青岛大学学报（医学版）》2022年第2期314-316,共3页Journal of Qingdao University(Medical Sciences)

基　　金：山东省医药卫生科技发展计划项目(2018WS379)。

摘　　要：近来研究表明,乙型肝炎核心抗体(HBcAb)与肝炎活动程度及药物治疗应答高度相关。本文主要对近年来HBcAb定量水平相关研究进行综述,以期为临床工作提供参考。Recent studies have shown that hepatitis B core antibody(HBcAb) is highly associated with the degree of he-patitis activity and the response to drug treatment. This article mainly reviews the studies on the quantification of HBcAb in recent years, so as to provide a reference for clinical work in the future.

关 键 词：乙型肝炎 乙型肝炎抗体 血清学试验 抗病毒药 综述 

分 类 号：R512.62[医药卫生—内科学]